Stimulating β-Cell Regeneration by Combining a GPR119 Agonist with a DPP-IV Inhibitor
Figure 7
(A) Immunostaining of insulin (red), BrdU (yellow) and DAPI (blue) in pancreas sections from BrdU-treated non-diabetic control mice and diabetic mice with restored normoglycemia after 7 weeks treatment with PSN632408, sitagliptin, or PSN632408 combined with sitagliptin.
White arrows indicate insulin/DAPI co-positive pancreatic duct cells. Green arrows indicate insulin/BrdU/DAPI co-positive pancreatic duct cells. (B) Immunostaining of insulin (red), CK19 (green), BrdU (yellow), and DAPI (blue) in pancreas sections from these mice. Red arrow indicates CK19/BrdU co-positive pancreatic duct cells. White arrows indicate insulin/CK19 co-positive pancreatic duct cells. (C) The percentage of ducts with insulin/CK19 co-positive cells was significantly increased in mice treated with PSN632408 alone or PSN632408 and sitagliptin combination compared with non-diabetic control mice (p<0.05, n = 3 to 6 mice per group).